This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Media
-
Changing of the guard at Race
The Board of Directors of Race Oncology wishes to advise that Dr. Peter Molloy has decided to step down as Managing Director and Chief Executive Officer. Chairman Dr John Cullity, and Chief Scientific Officer Dr Daniel Tillett will step into the interim roles of Executive Chairman and Chief Operating Officer, respectively. Dr Molloy, who has…
-
Race starts preclinical breast cancer study for Bisantrene
Race Oncology is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical Research Institute, will lead the project. The aim of this research program is to identify combinations of current breast cancer drugs that when…
-
Race raises A$1.8 million, appoints Non-Executive Chairman
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a strategic placement of six million ordinary shares, at an issue price of $0.30 per share. The placement has been anchored by biotechnology-focused institutional investor Merchant Opportunities Fund, which has a number of long-term strategic investments in the Australian biotechnology…
-
Race appoints Australian Clinical Program Director
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr Marinella Messina as its Australian Clinical Program Director. Dr Messina will commence of 16 March 2020 and will be responsible for progressing the Australian trials, part of the Company’s new ‘5 path’ strategy. Dr Messina has managed a wide range of clinical trials…
-
Professor Borje Andersson appointed Director of Race
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director. Prof Andersson is an internationally acclaimed leader in the fields of leukaemia and stem cell transplant research at MD Anderson Cancer Centre in Houston, Texas. Prof Andersson was previously engaged as a scientific and…
-
Prof Borje Andersson to Chair RAC Clinical Advisory Board
5 December 2019 – Race Oncology Limited (ASX: RAC) is honoured to advise that Professor Borje Andersson has agreed to chair Race Oncology’s Clinical Advisory Board (CAB). Prof Andersson is a world-recognised research leader in the field of leukaemia and stem cell transplantation at the MD Anderson Cancer Center in Houston, Texas. The appointment follows Prof…
-
Race Oncology 2019 Annual General Meeting Presentation
Overview of Race Oncology’s new “5 path” strategy for the development of Bisantrene. • Introduction & Welcome | Mr Peter Molloy CEO/MD (0.00 – 10.00) • Race’s 5 Path Strategy | Dr Daniel Tillett CSO (10.00 – 39.00) • Conclusion | Mr Peter Molloy CEO/MD (39.01 – 45.23) Videography and editing by Sirius Productions
-
Race reveals new strategy for cancer drug Bisantrene
14 November 2019 – Race Oncology Limited (ASX: RAC) today revealed its new “5 Path” clinical strategy for its cancer drug, Bisantrene. The strategy defines five paths for the clinical development of Bisantrene that greatly expands the addressable market for Bisantrene while reducing clinical development risk and targeting cancers beyond Acute Myeloid Leukaemia (AML). The new…
-
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019. Dr Tillett recently anchored a share placement in RAC and was recently appointed as a Non-Executive Director of RAC. Because of his new executive responsibilities, Dr Tillett’s Board role will change…